Merusの空売り状況は、投資家がMerusの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Merus (NASDAQ:MRUS) 株価情報, 空売り情報

Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Merus NV

Top Wall Street analysts initiated coverage on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Ben Kallo initiated coverage on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with an Outperform rating and announced a price target of $448. GE Vernova shares closed at $369.65 on Wednesday. <a href="https://www.benzinga.com/quote/GEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Joseph Catanzaro initiated coverage on Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with an Overweight rating and announced a price target of $84. Merus shares closed at $40.26 on Wednesday. <a href="https://www.benzinga.com/quote/MRUS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Scotiabank analyst George Farmer initiated coverage on Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Sector Outperform rating and announced a price target of $102. Viking Therapeutics shares closed at $29.32 on Wednesday. <a href="https://www.benzinga.com/quote/VKTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B. Riley Securities analyst Randy Binner initiated coverage on Sunrise Realty Trust, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) with a Buy rating and announced a price target of $15. Sunrise Realty Trust shares closed at $11.47 on Wednesday. <a href="https://www.benzinga.com/quote/SUNS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Julien Dumoulin-Smith initiated coverage on Fortis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTS#TSX">FTS</a>) with a Hold rating and announced a price target of C$67. <a href="https://www.benzinga.com/quote/FTS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="1006" height="505" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118.png" alt="" class="wp-image-780880" style="width:412px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118.png 1006w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118-300x151.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13080439/image-118-768x386.png 768w" sizes="(max-width: 1006px) 100vw, 1006px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/02/43655479/top-3-utilities-stocks-that-may-collapse-in-q1">Top 3 Utilities Stocks That May Collapse In Q1</a></li>
</ul>

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

MRUS

SUNS

TSX:FTS

VKTX

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Piper Sandler analyst Joseph Catanzaro initiates coverage on Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Overweight rating and announces Price Target of $84.

Price Target

Piper Sandler Initiates Coverage On Merus with Overweight Rating, Announces Price Target of $84

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) from Buy to Buy.

Reiteration

Guggenheim Reiterates Buy on Merusto Buy

"This manuscript provides comprehensive data on the safety and efficacy of Bizengri and demonstrates the meaningful results observed in the eNRGy trial," said&nbsp;Bill Lundberg, M.D., President, Chief Executive Officer of Merus. "We continue to make significant progress across our clinical pipeline of important and new cancer therapeutic candidates, all from our own Biclonics&nbsp;antibody technologies."

Merus Says New England Journal Of Medicine Published Results Of Registrational Phase 2 eNRGy Trial For Bizengri

Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) stock moved lower on Monday. The company announced a research collaboration and license agreement with Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>). Here&#8217;s <a href="https://www.benzinga.com//node/42936564">what you need to know.</a>
What To Know: Biohaven and Merus will to co-develop three antibody-based therapies, utilizing Merus&#8217; Biclonics platform alongside its own technologies. The collaboration includes two existing Merus programs and one in early research. 
Under the agreement, Merus will receive an upfront payment and a licensing fee once the first antibody drug conjugate (ADC) candidate is selected. In addition, Merus will cover the costs of preclinical antibody development, while Biohaven will manage the preclinical ADC development expenses. 
If any therapies progress to commercialization, the companies plan to share development costs jointly.
&#8220;We believe this collaboration with Merus will accelerate our ability to create highly differentiated multispecific ADCs, leveraging Biohaven&#8217;s innovative conjugation and payload technologies to deliver optimized ADCs with the potential to significantly benefit patients across various cancer types through an enhanced efficacy and safety profile,&#8221; added Brian Lestini, President, Oncology of Biohaven.
Related Link: <a href="https://www.benzinga.com/general/travel/25/01/42958773/united-airlines-earnings-preview-could-airline-impress-investors-after-deltas-strong-guidance">United Airlines Earnings Preview: Could Airline Impress Investors After Delta&#8217;s Strong Guidance?</a>
MRUS Price Action: Merus stock closed 7.75% lower on Monday at $40.45, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Photo: Shutterstock

Movers

BHVN

What's Going On With Merus Stock Monday?

WIIM

Merus shares are trading lower. The company announced a  research collaboration and license agreement with Biohaven to co-develop three novel bispecific antibody drug conjugates.

Reported Earlier, Merus And Biohaven Partner to Co-Develop Three Novel Bispecific Antibody Drug Conjugate (ADC) Programs

U.S. stocks were lower, with the Dow Jones index falling over 700 points on Friday.
Shares of TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose sharply in today's session after the company reported <a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10">better-than-expected quarterly financial results.</a>
Quarterly revenue of $15.85 billion, up 10% Y/Y, exceeded the analyst view of $15.22 billion. The Fremont, California-based company reported an adjusted EPS of $3.09, beating the street view of $3.05.
TD Synnex shares jumped 5.5% to $128.76 on Friday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Microvast Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares jumped 37.3% to $2.57 after the company announced a developments in its True All-Solid-State Battery technology.</li>
<li>Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) gained 23.6% to $11.40 after the company reported better-than-expected first-quarter financial results.</li>
<li>Savers Value Village Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SVV#NYSE">SVV</a>) surged 13.5% to $10.63 after the company reported preliminary fourth quarter and full year net sales.</li>
<li>Oculis Holding AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCS#NASDAQ">OCS</a>) gained 13.1% to $21.14.</li>
<li>Sasol Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) gained 13.1% to $4.99.</li>
<li>Pacira Biosciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) climbed 12.1% to $20.83 after the company reported a preliminary year-over-year increase in FY25 revenue.</li>
<li>Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) gained 10.6% to $28.97 after the company announced it increased its quarterly dividend.</li>
<li>Merus NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) gained 9.8% to $46.35.</li>
<li>Teekay Tankers Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) rose 8.1% to $45.56.</li>
<li>Talos Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TALO#NYSE">TALO</a>) gained 6.2% to $10.58.</li>
<li>TD Synnex Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) rose 5.5% to $128.76 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42912948/top-3-materials-stocks-that-are-set-to-fly-this-month">Top 3 Materials Stocks That Are Set To Fly This Month</a></li>
</ul>

Intraday Update

MVST

PCRX

RPRX

TALO

TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday

<a href="https://www.globenewswire.com/Tracker?data=NCrzNoU8yG3rqGkuad5oez3SzNsyzo2BctG8WH-FtL0Cds5D7DndYCzk5K4CaTbYNejhAylgOrnJYMb4e1eW1A==">Merus N.V</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics&#xAE; and Triclonics&#xAE;) for cancer, today announced that the first patient has been dosed in the Company's phase 2 trial evaluating petosemtamab monotherapy in heavily pretreated (3L+) metastatic colorectal cancer (mCRC). Petosemtamab is a Biclonics&#xAE;&nbsp;targeting EGFR and LGR5.&nbsp;
The phase 2, open-label trial will evaluate the safety and antitumor activity of petosemtamab&nbsp;monotherapy in 3L+ mCRC, post anti-EGFR therapy. To be eligible for enrollment, patients must lack certain mutations as detected in plasma by ctDNA NGS, including KRAS, NRAS.

Biotech

General

Merus announces First Patient Dosed In The Phase 2 Trial Evaluating Petosemtamab Monotherapy In Heavily Pretreated Metastatic Colorectal Cancer

Citigroup analyst Yigal Nochomovitz maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $89 to $97.

Citigroup Maintains Buy on Merus, Raises Price Target to $97

Needham analyst Ami Fadia reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

Needham Reiterates Buy on Merus, Maintains $85 Price Target

<ul>
<li>Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing HNSCC ongoing with clinical data update planned for 2025</li>
<li>Petosemtamab in mCRC evaluation expanded to include 1L and 3L+; initial clinical data planned for 2025</li>
</ul>

Reported Saturday, Merus Unveils Clinically Meaningful Activity For Petosemtamab In 2L+ R/M HNSCC And Expands Evaluation In mCRC

On Wednesday, the FDA approved Merus N.V.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) Bizengri&nbsp;(zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42328116/merus-announces-fda-approval-of-bizengri-zenocutuzumab-zbco-for-nrg1-pancreatic-adenocarcinoma-and" rel="noreferrer noopener">prior systemic therapy</a>.
Bizengri is Merus&#8217;s first approved medicine and is based on the proprietary&nbsp;Biclonics technology platform.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42272645/merus-licenses-us-commercialization-rights-for-cancer-potential-zenocutuzumab-analyst-highlight-merus-pipeline" rel="noreferrer noopener">Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus&#8217; Pipeline</a>
These indications are approved under accelerated approval based on the overall response rate (ORR) and duration of response (DOR).
Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Bizengri&nbsp;20 mg/mL Injection for Intravenous Use is expected to be available to patients in the coming weeks.
Bizengri&#8217;s approval&nbsp;is based on data from the eNRGy trial. In patients with&nbsp;NRG1+ pancreatic adenocarcinoma (n=30), Bizengri&nbsp;demonstrated an ORR of 40%.
DOR in&nbsp;NRG1+ pancreatic adenocarcinoma ranged from 3.7 months to 16.6 months. In the same trial, patients with&nbsp;NRG1+ NSCLC (n=64) treated with Bizengri&nbsp;demonstrated an ORR of 33%. The median DOR in&nbsp;NRG1+ NSCLC was 7.4 months.
b writes, &#8220;Investor focus remains on petosemtamab, with the next key catalyst for the company being updated data for petosemtamab in previously treated head and neck squamous cell carcinoma (HNSCC) at ESMO Asia on December 7.&#8221;
The analyst assumes Bizengri will be priced at roughly $30,000 per treatment and estimates combined peak U.S. sales in NRG1 fusion NSCLC and PDAC attributable to Merus (based on an estimated 8% royalty rate) of roughly $16.5 million.
Price Action: MRUS stock is down 3.70% at $43.80 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42324351/fda-approved-sickle-cell-therapies-from-bluebird-bio-and-vertex-join-medicaid-innovation-program" target="_blank" rel="noreferrer noopener">FDA-Approved Sickle Cell Therapies From Bluebird Bio And Vertex Join Medicaid Innovation Program</a></li>
</ul>

Analyst Color

Health Care

Merus Scores Its First FDA Approval For Lung Cancer Drug

Guggenheim analyst Michael Schmidt maintains Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and raises the price target from $93 to $111.

Guggenheim Maintains Buy on Merus, Raises Price Target to $111

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Merus N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) is still &#8220;very,<a href="https://www.benzinga.com/quote/mrus/earnings"> very speculative.&#8221;</a>
On Wednesday, Merus announced the FDA approval of BIZENGRI for NRG1+ pancreatic adenocarcinoma and NRG1+ non–small cell lung cancer based on safety and efficacy data from the eNRGy study.
&#8220;Storied company, terrific. It does great,&#8221; Cramer said when asked about Allison Transmission Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>). &#8220;I actually would prefer you to swap out right now and go to be with Mary Barra at GM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>). Cheaper and will be just as good.&#8221;
On Oct.29, Allison Transmission reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance.
NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) has &#8220;no earnings,&#8221; Cramer said. &#8220;I want you to take out almost all of your cost basis and let the rest run.&#8221;
On Dec. 4, the company earlier announced a Memorandum of Understanding (MOU) with the U.S. Department of Energy's Idaho Operations Office to explore siting, construction and operation of its proprietary ‘ZEUS&#8217; and ‘ODIN&#8217; microreactors at the <a href="https://www.benzinga.com/news/24/12/42323743/whats-going-on-with-nano-nuclear-energy-nne-stock">Idaho National Laboratory (INL).</a>
&#8220;It is living off, I think, a lot of the federal money that's been spent. So, I don't want to get greedy,&#8221; Cramer said when asked about Sterling Infrastructure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRL#NASDAQ">STRL</a>). He recommended taking some off the table and let the rest run.
On Nov. 6, Sterling Infrastructure reported worse-than-expected third-quarter revenue results and lowered the top end of its FY24 revenue guidance.
Price Action:
<ul>
<li>Allison Transmission shares gained 0.9% to settle at $117.95 on Wednesday.</li>
<li>Nano Nuclear Energy shares fell 0.5% to close at $26.50.</li>
<li>Sterling Infrastructure shares gained 1.7% to close at $198.82 on Wednesday.</li>
<li>Merus shares fell 1.6% to settle at $45.49 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42313903/top-3-tech-and-telecom-stocks-that-may-implode-this-quarter">Top 3 Tech And Telecom Stocks That May Implode This Quarter</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

ALSN

STRL

Jim Cramer: This Health Care Stock Is 'Very, Very Speculative'

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and maintains $85 price target.

HC Wainwright & Co. Reiterates Buy on Merus, Maintains $85 Price Target

<ul>
<li>BIZENGRI&#xAE; is the first and only therapy approved by the FDA specifically for pancreatic adenocarcinoma and NSCLC that harbor NRG1 gene fusions and are advanced unresectable or metastatic1</li>
<li>Merus and Partner Therapeutics announced a license agreement for U.S. commercialization</li>
</ul>
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=ex5f2gygbCiuJdH_pXLq4WKCDbHu1pHyh3pZ1HZo_2uFBcbeJdnK5mE1HgnqqSDsuIwevPpmuqgNxIgdlI4XaQ==">Merus N.V.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) [Merus, the Company, we, or our], a clinical-stage oncology company developing innovative, full-length, multispecific antibodies (Biclonics&#xAE;&nbsp;and Triclonics&#xAE;), announced today that the U.S. Food and Drug Administration (FDA) approved BIZENGRI&#xAE; (zenocutuzumab-zbco), the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) that are advanced unresectable or metastatic and harbor a neuregulin 1 (NRG1) gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BIZENGRI&#xAE; has a Boxed WARNING for Embryo-Fetal Toxicity and warnings for infusion-related reactions (IRRs), hypersensitivity and anaphylactic reactions, interstitial lung disease (ILD)/pneumonitis, and left ventricular dysfunction.1 See Important Safety Information below.
We believe this approval fills an important need for patients with NRG1+ cancer who have not previously had treatment options approved to specifically target this driver. BIZENGRI&#xAE; (zenocutuzumab-zbco) 20 mg/mL Injection for Intravenous Use is expected to be available to patients in the coming weeks.

Merus Announces FDA Approval Of BIZENGRI For NRG1+ Pancreatic Adenocarcinoma And NRG1+ Non–Small Cell Lung Cancer Based On Safety And Efficacy Data From The eNRGy Study

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelera[…]al-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic</a>

FDA Grants Accelerated Approval To Zenocutuzumab-zbco For Non-Small Cell Lung Cancer And Pancreatic Adenocarcinoma

Guggenheim analyst Michael Schmidt reiterates Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) with a Buy and lowers the price target from $111 to $109.

Guggenheim Reiterates Buy on Merus, Lowers Price Target to $109

Merus and Biohaven to co-develop three novel bispecific ADC programs

Biohaven (BHVN) announced a multi-target collaboration with Merus (MRUS). This collaboration will co-develop three programs encompassing highly dif...

Biohaven enters multi-target collaboration with Merus

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of $73.0...

Bank of America Securities Sticks to Its Buy Rating for Merus (MRUS)

Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report) and keeping the price target at $100.00. Charles...

Merus's Promising Clinical Trials and Strategic Collaborations Highlight Attractive Investment Potential

In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Merus (MRUS – Research Report). The company's sha...

Truist Financial Sticks to Its Buy Rating for Merus (MRUS)

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Roblox downgraded, Pinterest upgraded: Wall Street's top analyst calls

Piper Sandler initiated coverage of Merus (MRUS) with an Overweight rating and $84 price target The firm views the company's EGFRxLGR5 bispecific, ...

Merus initiated with an Overweight at Piper Sandler

Merus (MRUS) has received a new Buy rating, initiated by Piper Sandler analyst, Joseph Catanzaro. Joseph Catanzaro's rating is based on a combinati...

Analyst Recommends Buy for Merus Based on Promising Petosemtamab Developments and Revenue Potential

Target downgraded, Cisco upgraded: Wall Street's top analyst calls

CSCO

CYTK

DECK

DOCS

HUBS

ILMN

JAZZ

LMAT

PINS

RBLX

Earnings

Press Releases

Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update

Merus Receives FDA extension of PDUFA for zenocutuzumab

Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024

Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Comments

Merus

空売り

Merus (NASDAQ:MRUS) 株価情報, 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル